Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | BRD2 | P25440 | 4/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30111763 | 1.00 | BRD4 (0.41) | BRD4BRD2BRD3NOTUMGABRB3 | |
| SCHEMBL30111768 | 1.00 | BRD4 (0.41) | BRD4BRD2BRD3NOTUMGABRB3 | |
| SCHEMBL12530565 | 0.81 | NPC1 (0.47) | BRD4BRD2BRD3NOTUMGABRB3 | |
| SCHEMBL2687696 | 0.80 | KCNN4 (0.50) | NOTUMKMT2A | |
| SCHEMBL21834180 | 0.76 | NOTUM (0.62) | BRD4BRD2BRD3NOTUMNPC1 | |
| SCHEMBL31274376 | 0.74 | NOTUM (0.34) | NOTUMGABRB3 | |
| SCHEMBL28906175 | 0.74 | ALDH1A1 (0.51) | BRD4BRD2BRD3LMNA | |
| SCHEMBL30261931 | 0.73 | L3MBTL1 (0.32) | — | |
| SCHEMBL24034796 | 0.72 | L3MBTL1 (0.32) | KMT2A | |
| SCHEMBL25045453 | 0.71 | NOTUM (0.42) | NOTUMGABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149933-B1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2024-06-12 | — | — | EP | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021228795-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRA3, GABRB3 | BRD4 1577/4885BRD2 2146/4885BRD3 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.